Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories snagged a CE mark for its Volt pulsed field ablation catheter for atrial fibrillation several months earlier than the mid-year approval expected. The Abbott Park, Ill.-based ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

We recently published a list of the 10 Best S&P 500 Stocks to Buy for Dividend Growth. In this article, we are going to take ...

Abbott (ABT) announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. With the ...